W Hotels Worldwide Makes Waves with the Debut of W Amsterdam
W Hotels Worldwide, part of Starwood Hotels & Resorts Worldwide, Inc. (NYSE:HOT), today debuted in the Netherlands with the highly anticipated opening of W Amsterdam. Owned by Europe Hotels | Private Collection, the hotel brings the W brand’s distinctive New York energy, Whatever/Whenever® service mentality and upbeat programming to the Dutch capital. Just steps away from the vibrant Dam Square and the Royal Palace, the hotel introduces WET DECK®, the city’s first rooftop pool, and electrifying culinary venues, such as THE DUCHESS and MR PORTER.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151022005538/en/
W Amsterdam features WET®, Amsterdam’s first rooftop pool, offering views of the Royal Palace and lively historic centre (Photo: Business Wire).
“The long awaited and much anticipated opening of W Amsterdam brings a distinctive new take on hospitality to the heart of the city,” said Anthony Ingham, Global Brand Leader of W Hotels Worldwide. “Amsterdam has emerged as a world leader in design, music and fashion, all of which have long been passions of W Hotels and our global travelers. As one of Europe’s most popular destinations, we are excited to welcome guests and locals alike to an energetic space full of unexpected moments.”
Located in the epicentre of Amsterdam’s vibrant social scene, the 238-room hotel spans two iconic buildings, one of which used to house the former Telephone Exchange (‘Exchange’) and the other was previously home to KAS Bank (‘Bank’). W Amsterdam was designed by Office WINHOV and Baranowitz Kronenberg Architects, who collaborated with local designers to refresh the historic buildings with contemporary features inspired by their storied past.
“Amsterdam’s progressive spirit is a perfect match for W Hotels. We are thrilled to introduce a new style of modern hospitality to the Netherlands in partnership with Europe Hotels | Private Collection and its owner, Liran Wizman, who share our vision for W Hotels,” said Michael Wale, President, Starwood Hotels & Resorts Worldwide, Europe, Middle East and Africa. “W Amsterdam is our first W Hotel in the country and reinforces Starwood’s commitment to grow our presence in this important European market.”
Connect and Exchange in the Heart of Amsterdam
The Exchange building features 172 stylish guest rooms, while the 66 rooms in the Bank will open early next year. The hotel will have a total of 21 suites, three WOW suites and two lavish Extreme WOW suites – the W brand’s take on the Presidential suite. Boasting an impressive 183 square metres of innovative design, an open plan bathroom complete with a hot tub, walk-in wardrobe and large round bed with extraordinary views of the Royal Palace, the Extreme WOW Suite is the city’s most glamourous crash pad. W Amsterdam features SPG Keyless, the hospitality industry’s first keyless entry system enabling guests to use their smartphone or wearable device as a room key.
Guests arrive in style when they check in at the rooftop W Lounge, the W brand’s re-interpretation of the traditional hotel lobby, on the sixth floor of the Exchange building. With four outdoor terraces and floor-to-ceiling windows, guests can enjoy spectacular 360-degree views over canal houses and heritage sites. Looking out to the Royal Palace and lively historic centre, WET DECK is Amsterdam’s first rooftop pool. Spanning 22 metres and heated in winter, WET DECK is where Amsterdam’s style-savvy locals mix it up over open air cocktails and city scape views. Also located on the rooftop, MR PORTER blends qualities of a modern steakhouse with the sophisticated ambiance of a chic, high-energy lounge.
Across the street in the Bank building, THE DUCHESS opened in June to rave reviews, combining an eclectic taste of London and Viennese grandeur. The building also houses FIT ® state-of-the-art fitness centre; a spa located amid the original bank vaults; and XBANK, a 700 square metre exhibition gallery and immersive creative incubator concept space that connects local design, fashion and music talents – all of which will be unveiled in early 2016 together with the remaining guest rooms.
W Amsterdam will offer 414 square metres of ultra-modern meeting and event space, including a Great Room which can be divided into three smaller meeting rooms.
“The opening of W Amsterdam marks the pinnacle of Amsterdam’s rapid growth as one of Europe’s most popular destinations for jet setting travellers,” said Liran Wizman, owner of W Amsterdam and Europe Hotels | Private Collection. “With its innovative lifestyle programming and two distinctive restaurants set to shake-up the capitals hospitality scene, W Amsterdam will bring something new and exciting to the hotel industry in the Dutch capital.”
Starwood in the Netherlands
With the opening of W Amsterdam, Starwood now has three hotels in the Netherlands – including Sheraton Amsterdam Airport Hotel Schiphol and Hotel Des Indes, a Luxury Collection Hotel, The Hague. The company will continue to expand its Dutch portfolio with the debut of Element Amsterdam in early 2016.
Rooms at W Amsterdam are available from €350 per night. For more information visit www.wamsterdam.com or follow @WAmsterdamHotel on Twitter and Instagram with the hashtag #WXXX.
# # #
About W Hotels Worldwide
W Hotels is a contemporary, design-led luxury lifestyle brand and the industry innovator with 47 hotels and retreats, including 17 W-branded residences, in the most vibrant cities and exotic destinations around the world. Inspiring, iconic, innovative and influential, W Hotels provides the ultimate in insider access, offering a unique mix of cutting-edge design and passions around fashion, music and entertainment. With 15 years of proven success, W Hotels is on track to reach more than 60 hotels by 2018. W Hotels have been announced for Shanghai, Tel Aviv, Abu Dhabi, Dubai, Amman, Jakarta, Panama, Muscat, Suzhou, Changsha, Chengdu, New Delhi, Kuala Lumpur, Shenyang, Marrakech and Brisbane, while upcoming W Retreats include Goa, Phuket, Hainan Island and Mexico’s Riviera Maya. For more information, visit whotels.com or follow Twitter, Instagram and Facebook.
Starwood Hotels & Resorts Worldwide, Inc.
Julien Guitard, Tel. +32 2 204 5160
Associate Director Communications – Europe, Africa & Middle East Starwood Hotels & Resorts
Angelina Hue, Tel. +32 2 204 5518
Manager Brand Communications & Events – Europe, Africa & Middle East
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19 | Pressemelding
Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom